Market Overview

UPDATE: Credit Suisse Downgrades Infinity Pharmaceuticals on Limited Clinical News in 2014

Share:
Related INFI
44 Biggest Movers From Friday
35 Stocks Moving In Friday's Mid-Day Session

In a report published Thursday, Credit Suisse analyst Jason Kantor downgraded the rating on Infinity Pharmaceuticals (NASDAQ: INFI) from Outperform to Neutral, but reiterated the $20.00 price target.

In the report, Credit Suisse noted, “We are downgrading INFI to Neutral because (1) limited clinical data is expected in 2014, (2) an increasingly complex competitive landscape, which we think is evolving to favor BTK inhibitors and ABT-199 over PI3K inhibitors; and (3) risk of class effect safety issues or drug specific safety issues, although initial concerns over infections and liver enzymes seem to have cooled down.”

Infinity Pharmaceuticals closed on Wednesday at $13.31.

Latest Ratings for INFI

DateFirmActionFromTo
Oct 2017Wells FargoUpgradesMarket PerformOutperform
Jun 2016Morgan StanleyDowngradesOverweightEqual-Weight
Jun 2016William BlairDowngradesOutperformMarket Perform

View More Analyst Ratings for INFI
View the Latest Analyst Ratings

Posted-In: Credit Suisse Jason KantorAnalyst Color Downgrades Analyst Ratings

 

Related Articles (INFI)

View Comments and Join the Discussion!

Partner Center